Developer docs
API playgroundTry for free, no card

Search company profiles

Oramed Pharmaceuticals

Full company profile

uuid00035em

Namestring
Oramed Pharmaceuticals
Legal namestring
Oramed Pharmaceuticals Inc.
Websiteurl
oramed.com
Company typeenum
Public
Founded yearint
2006
Descriptiontext

Oramed Pharmaceuticals Inc. (NASDAQ/TASE: ORMP) is a clinical-stage pharmaceutical company founded in 2006 that has developed a proprietary Protein Oral Delivery (POD™) platform — a formulation technology originating from over 30 years of research at Jerusalem's Hadassah Medical Center — designed to protect protein and peptide drugs through the gastrointestinal tract and enable oral administration of therapeutics normally delivered by injection. Its lead asset is ORMD-0801, an oral insulin capsule for Type 2 diabetes (and under evaluation for NASH), with a broader pipeline that includes ORMD-0901 (oral exenatide/GLP-1) and combination insulin/GLP-1 capsules, all protected by a multi-jurisdiction patent estate.

The company's revenue mechanics are unusual for a clinical-stage biotech: commercial product revenue is effectively absent, while reported earnings have been driven by financial engineering — primarily a $101.875M senior secured note to Scilex Holding Company (with attached warrants), a $36.9M strategic equity investment in Alpha Tau Medical, and a transformative 2026 transaction with Lifeward Ltd. in which Oramed transferred the POD technology for up to 49.99% equity in Lifeward plus milestone and royalty rights (4% on ReWalk franchise sales for up to 10 years). Distribution partnerships span China (HTIT, now terminated), South Korea (Medicox), and Mexico/Latin America (Genomma Lab JV via Oravax Medical), but forward commercialization of ORMD-0801 is now being pursued independently via a planned 60-patient US-based trial.

Operationally, Oramed runs a lean organization (11–50 employees) with corporate headquarters in New York and R&D anchored in Jerusalem. As of March 31, 2026, total cash and assets stood at approximately $270M, and the company reported $65M of net income for the nine months ended September 30, 2025, almost entirely attributable to investment gains and Scilex repayments rather than pharmaceutical sales. The investment thesis hinges on whether ORMD-0801 can be repositioned for regulatory success after the 2023 Phase 3 discontinuation, while the balance sheet and portfolio provide multi-year runway and optionality through strategic holdings in Scilex, Alpha Tau, and Lifeward.

Short descriptiontext

Oramed Pharmaceuticals is a clinical-stage biopharmaceutical company developing oral formulations of injectable protein drugs — led by an oral insulin capsule (ORMD-0801) — using its proprietary Protein Oral Delivery (POD™) platform, and operating alongside a diversified portfolio of strategic biomedical investments.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersJerusalem, Israel
HQ citystring
Jerusalem
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oral drug delivery, oral insulin therapy, clinical-stage pharmaceuticals, protein therapeutics, diabetes treatment
Industry1 code
PRIMARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Oral Insulin and Diabetes Therapeutics
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Strategic Investment Returns
TypeLicensing Royalties
Description

Oramed generates returns through investments in biomedical companies including Scilex Holdings (loan repayments with interest), Alpha Tau Medical (equity appreciation), BioXcel Therapeutics, and Pelthos Therapeutics. The company received approximately $118 million in Scilex repayments as of early 2026 with expected total recovery of ~$161 million on original $99.5 million loan.

prnewswire.com
2Warrant and Equity Holdings
TypeTransaction Fee
Description

Oramed holds warrants to purchase Scilex shares (originally 6.5 million warrants at $0.01 exercise price) and receives proceeds from warrant repurchases. Also holds 49.9% beneficial ownership stake in Lifeward and ~14.1 million shares in Alpha Tau Medical valued at approximately $167 million.

oramed.com
3Technology Licensing and Royalties
TypeLicensing Royalties
Description

Oramed licenses its POD technology to partners. Royalty arrangement with Lifeward includes 4% royalties on ReWalk franchise net sales for up to 10 years. Distribution agreements with Medicox (South Korea) and potential China commercialization via HTIT.

prnewswire.com
4Pharmaceutical Development
TypeLicensing Royalties
Description

Core business of developing oral delivery formulations for injectable drugs. Revenue potential from FDA-approved oral insulin (ORMD-0801) targeting the $600+ billion injectable drugs market.

oramed.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1POD (Protein Oral Delivery)
Description

Oramed's novel Protein Oral Delivery technology designed to protect drug integrity and increase absorption for oral administration of injectable drugs.

oramed.com
Core offering1 text field

Oramed is a clinical-stage pharmaceutical company developing its proprietary Protein Oral Delivery (POD™) platform technology, which enables oral administration of drugs currently delivered by injection. Its lead clinical candidates are ORMD-0801, an oral insulin capsule targeting Type 2 diabetes (and under evaluation for NASH), and ORMD-0901, an oral GLP-1 analog (exenatide) capsule. The company also licenses/transfer the POD platform to partners (e.g., Lifeward, HTIT, Medicox, Genomma Lab) and holds strategic biomedical investments in companies such as Scilex Holding and Alpha Tau Medical.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 0.81% placebo-adjusted A1C reduction at 8mg once daily dose (p=0.028)
+3 more records
Product overview1 text field

Oramed Pharmaceuticals is a clinical-stage pharmaceutical company and platform technology pioneer in oral delivery solutions for drugs currently delivered via injection. The company operates a platform-plus-products model centered on its proprietary Protein Oral Delivery (POD™) technology. The core product portfolio includes ORMD-0801 (oral insulin capsule for Type 2 diabetes and NASH treatment) and ORMD-0901 (oral GLP-1 analog capsule), both leveraging the POD platform. The company has undergone strategic transformation, having transferred its POD technology to Lifeward while maintaining responsibility for the POD clinical program. Oramed maintains strategic investments in biomedical firms including Scilex Holdings, Alpha Tau Medical, and maintains a joint venture relationship with Hefei Tianhui Biotech (HTIT) for oral insulin development in China.

Product and service3 records
1ORMD-0801 (Oral Insulin Capsule)
CategoryOral Insulin / Anti-Diabetic Pharmaceutical
Description

Oral insulin capsule candidate intended to be the first commercial oral insulin for treatment of Type 2 diabetes (with additional evaluation for Type 1 diabetes and NASH); based on POD™ technology to protect drug integrity and increase absorption across the gastrointestinal tract. Phase 2b data showed a 0.81% placebo-adjusted A1C reduction at 8mg dose (p=0.028) with no serious drug-related adverse events, hypoglycemia, or weight gain.

2ORMD-0901 (Oral GLP-1 Analog / Exenatide Capsule)
CategoryOral GLP-1 Analog / Anti-Diabetic Pharmaceutical
Description

Oral GLP-1 analog (exenatide) capsule for diabetes treatment with potential weight-loss benefits, leveraging the POD™ technology platform. Protected by a granted U.S. patent for oral administration of exenatide.

3Protein Oral Delivery (POD™) Technology Platform — Licensing
CategoryDrug Delivery Technology Platform / Out-licensing
Description

Proprietary Protein Oral Delivery (POD™) platform technology licensed and transferred to commercialization partners (e.g., Lifeward globally) for oral administration of proteins and peptides historically delivered by injection. Protected by granted U.S., European, and international patents covering oral insulin, oral exenatide, and combination insulin+GLP-1 capsules.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-13
Description

Strategic partnership where Oramed transferred its clinical-stage Protein Oral Delivery (POD) technology to Lifeward, receiving up to 49.99% equity ownership in return. Deal valued at up to $47 million through equity, convertible notes, milestone-based funding, and warrant coverage. Oramed retains responsibility for POD clinical program including planned 60-patient U.S. trial for ORMD-0801. Oramed also receives 4% royalties on ReWalk franchise net sales for up to 10 years.

2Hefei Tianhui Biotech Co. Ltd. (HTIT)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-23
Description

Joint venture with Chinese partner HTIT for oral insulin development and commercialization. HTIT completed Phase 3 oral insulin trials in China and submitted Marketing Authorization Application to NMPA. HTIT committed $70 million in cash to the JV while Oramed invested $25 million in cash and stock. Oramed terminated the joint venture in 2025 to proceed independently with its oral insulin program.

prnewswire.com
Strategic tierRegionalTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-11-18
Description

Distribution agreement with Medicox for commercialization of oral insulin in South Korea. Oramed signed definitive deal for oral insulin distribution through Medicox's established pharmaceutical distribution network.

Strategic tierRegionalTypeStrategic or Co-development PartnerAnnounced on2021-11-18
Description

Joint venture between Oramed's subsidiary Oravax Medical and Genomma Lab for development and commercialization of oral COVID-19 vaccine in Mexico and Latin America. Genomma Lab brings local market expertise and distribution capabilities.

5Hadassah Medical Center
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2018-02-28
Description

POD technology based on over 30 years of research by scientists at Jerusalem's Hadassah Medical Center. The research partnership provides the foundational scientific basis for Oramed's oral delivery platform technology.

oramed.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Major insulin manufacturer (Lantus, Toujeo, Apidra) with established global diabetes infrastructure. Sanofi represents incumbent competition for any oral insulin entrant and has the resources to develop or acquire competing oral delivery technology.

TypeEmerging player
Description

Clinical-stage company developing oral hepatic-directed vesicle (HDV) insulin and other liver-targeted therapies for diabetes. Diasome is an emerging player working on alternative oral insulin delivery approaches with comparable patient target.

TypeEmerging player
Description

Clinical-stage peptide therapeutics company developing long-acting GLP-1 analogs and other peptide-based treatments. Zealand Pharma is an emerging peer in the GLP-1 space, directly relevant to Oramed's ORMD-0901 oral exenatide program.

TypeEmerging player
Description

Developed an implantable osmotic pump for continuous delivery of diabetes therapies, representing another approach to reducing injection burden. Intarcia is a thematically comparable emerging peer in long-acting / non-injectable diabetes delivery.

TypeBroad incumbent
Description

Global leader in diabetes care with dominant insulin and GLP-1 franchises (Ozempic, Wegovy, Rybelsus — the only currently approved oral GLP-1). Novo Nordisk is the primary competitive incumbent Oramed would face in any oral insulin or oral GLP-1 launch.

TypeDirect peer
Description

French clinical-stage biotech developing oral formulations of insulin and GLP-1 analogs using BioChaperone technology. Adocia is the closest direct competitor in oral peptide delivery; Oramed's VP of Medical Affairs (Dr. Simon Bruce) was formerly CMO of Adocia.

TypeEmerging player
Description

India-based biosimilar insulin and biologic manufacturer with growing global commercial reach. Biocon is an emerging peer in the broader insulin market and a potential strategic partner or competitor for affordable insulin analogs.

TypeBroad incumbent
Description

Major diabetes/obesity player with injectable insulin and the leading injectable GLP-1 franchise (Mounjaro/Zepbound). Lilly's scale, manufacturing, and commercial reach make it a direct competitive threat to any oral diabetes entrant.

TypeDirect peer
Description

Developed and commercializes Afrezza, an inhaled insulin, addressing the same unmet need Oramed targets: reducing the injection burden for diabetes patients. MannKind is a directly comparable non-invasive insulin delivery peer.

TypeEmerging player
Description

Clinical-stage company developing orally bioavailable small molecules for type 1 diabetes (TTP399) and other metabolic diseases. vTv is an emerging peer in oral diabetes therapeutics, though pursuing a different mechanism than peptide delivery.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment4 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Oramed Pharmaceuticals

Oral Insulin and Diabetes Therapeuticsoramed.com

Oramed Pharmaceuticals is a clinical-stage biopharmaceutical company developing oral formulations of injectable protein drugs — led by an oral insulin capsule (ORMD-0801) — using its proprietary Protein Oral Delivery (POD™) platform, and operating alongside a diversified portfolio of strategic biomedical investments.

What Oramed Pharmaceuticals does

Oramed Pharmaceuticals Inc. (NASDAQ/TASE: ORMP) is a clinical-stage pharmaceutical company founded in 2006 that has developed a proprietary Protein Oral Delivery (POD™) platform — a formulation technology originating from over 30 years of research at Jerusalem's Hadassah Medical Center — designed to protect protein and peptide drugs through the gastrointestinal tract and enable oral administration of therapeutics normally delivered by injection. Its lead asset is ORMD-0801, an oral insulin capsule for Type 2 diabetes (and under evaluation for NASH), with a broader pipeline that includes ORMD-0901 (oral exenatide/GLP-1) and combination insulin/GLP-1 capsules, all protected by a multi-jurisdiction patent estate.

The company's revenue mechanics are unusual for a clinical-stage biotech: commercial product revenue is effectively absent, while reported earnings have been driven by financial engineering — primarily a $101.875M senior secured note to Scilex Holding Company (with attached warrants), a $36.9M strategic equity investment in Alpha Tau Medical, and a transformative 2026 transaction with Lifeward Ltd. in which Oramed transferred the POD technology for up to 49.99% equity in Lifeward plus milestone and royalty rights (4% on ReWalk franchise sales for up to 10 years). Distribution partnerships span China (HTIT, now terminated), South Korea (Medicox), and Mexico/Latin America (Genomma Lab JV via Oravax Medical), but forward commercialization of ORMD-0801 is now being pursued independently via a planned 60-patient US-based trial.

Operationally, Oramed runs a lean organization (11–50 employees) with corporate headquarters in New York and R&D anchored in Jerusalem. As of March 31, 2026, total cash and assets stood at approximately $270M, and the company reported $65M of net income for the nine months ended September 30, 2025, almost entirely attributable to investment gains and Scilex repayments rather than pharmaceutical sales. The investment thesis hinges on whether ORMD-0801 can be repositioned for regulatory success after the 2023 Phase 3 discontinuation, while the balance sheet and portfolio provide multi-year runway and optionality through strategic holdings in Scilex, Alpha Tau, and Lifeward.

Oramed Pharmaceuticals firmographics

Firmographics
Name
Oramed Pharmaceuticals
Legal name
Oramed Pharmaceuticals Inc.
Website
https://oramed.com
Company type
Public
Founded year
2006
Operating status
Operating
Headcount range
11–50 employees
Short description
Oramed Pharmaceuticals is a clinical-stage biopharmaceutical company developing oral formulations of injectable protein drugs — led by an oral insulin capsule (ORMD-0801) — using its proprietary Protein Oral Delivery (POD™) platform, and operating alongside a diversified portfolio of strategic biomedical investments.
Ownership category
akta.pro rank

Oramed Pharmaceuticals industry classification

Industry
Product category
Oral Insulin and Diabetes Therapeutics
NAICS
Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Oral drug delivery
  • Oral insulin therapy
  • Clinical-stage pharmaceuticals
  • Protein therapeutics
  • Diabetes treatment

Where Oramed Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Jerusalem
HQ country
Israel
HQ region
Middle East

Offices2 records

Markets served

Oramed Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Strategic Investment Returns: Oramed generates returns through investments in biomedical companies including Scilex Holdings (loan repayments with interest), Alpha Tau Medical (equity appreciation), BioXcel Therapeutics, and Pelthos Therapeutics. The company received approximately $118 million in Scilex repayments as of early 2026 with expected total recovery of ~$161 million on original $99.5 million loan.
  2. Warrant and Equity Holdings: Oramed holds warrants to purchase Scilex shares (originally 6.5 million warrants at $0.01 exercise price) and receives proceeds from warrant repurchases. Also holds 49.9% beneficial ownership stake in Lifeward and ~14.1 million shares in Alpha Tau Medical valued at approximately $167 million.
  3. Technology Licensing and Royalties: Oramed licenses its POD technology to partners. Royalty arrangement with Lifeward includes 4% royalties on ReWalk franchise net sales for up to 10 years. Distribution agreements with Medicox (South Korea) and potential China commercialization via HTIT.
  4. Pharmaceutical Development: Core business of developing oral delivery formulations for injectable drugs. Revenue potential from FDA-approved oral insulin (ORMD-0801) targeting the $600+ billion injectable drugs market.

Go-to-market motion3 records

Distribution channels6 records

Marketing channels5 records

Oramed Pharmaceuticals product offering

Product offering

Core offering

Oramed is a clinical-stage pharmaceutical company developing its proprietary Protein Oral Delivery (POD™) platform technology, which enables oral administration of drugs currently delivered by injection. Its lead clinical candidates are ORMD-0801, an oral insulin capsule targeting Type 2 diabetes (and under evaluation for NASH), and ORMD-0901, an oral GLP-1 analog (exenatide) capsule. The company also licenses/transfer the POD platform to partners (e.g., Lifeward, HTIT, Medicox, Genomma Lab) and holds strategic biomedical investments in companies such as Scilex Holding and Alpha Tau Medical.

Product overview

Oramed Pharmaceuticals is a clinical-stage pharmaceutical company and platform technology pioneer in oral delivery solutions for drugs currently delivered via injection. The company operates a platform-plus-products model centered on its proprietary Protein Oral Delivery (POD™) technology. The core product portfolio includes ORMD-0801 (oral insulin capsule for Type 2 diabetes and NASH treatment) and ORMD-0901 (oral GLP-1 analog capsule), both leveraging the POD platform. The company has undergone strategic transformation, having transferred its POD technology to Lifeward while maintaining responsibility for the POD clinical program. Oramed maintains strategic investments in biomedical firms including Scilex Holdings, Alpha Tau Medical, and maintains a joint venture relationship with Hefei Tianhui Biotech (HTIT) for oral insulin development in China.

Differentiator

Problem solved

Functional benefit

Brands

  • POD (Protein Oral Delivery): Oramed's novel Protein Oral Delivery technology designed to protect drug integrity and increase absorption for oral administration of injectable drugs.

Products and services

  • ORMD-0801 (Oral Insulin Capsule) Oral insulin capsule candidate intended to be the first commercial oral insulin for treatment of Type 2 diabetes (with additional evaluation for Type 1 diabetes and NASH); based on POD™ technology to protect drug integrity and increase absorption across the gastrointestinal tract. Phase 2b data showed a 0.81% placebo-adjusted A1C reduction at 8mg dose (p=0.028) with no serious drug-related adverse events, hypoglycemia, or weight gain.
  • ORMD-0901 (Oral GLP-1 Analog / Exenatide Capsule) Oral GLP-1 analog (exenatide) capsule for diabetes treatment with potential weight-loss benefits, leveraging the POD™ technology platform. Protected by a granted U.S. patent for oral administration of exenatide.
  • Protein Oral Delivery (POD™) Technology Platform — Licensing Proprietary Protein Oral Delivery (POD™) platform technology licensed and transferred to commercialization partners (e.g., Lifeward globally) for oral administration of proteins and peptides historically delivered by injection. Protected by granted U.S., European, and international patents covering oral insulin, oral exenatide, and combination insulin+GLP-1 capsules.

Quantifiable outcome

  • 0.81% placebo-adjusted A1C reduction at 8mg once daily dose (p=0.028)
  • +3 more outcomes

Companies that use Oramed Pharmaceuticals

Customer profile

Segments4 records

Ideal customer profiles2 records

Oramed Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Oramed Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and regional.

  • Lifeward Ltd.coreStrategic or Co-development Partner · 13 January 2026Strategic partnership where Oramed transferred its clinical-stage Protein Oral Delivery (POD) technology to Lifeward, receiving up to 49.99% equity ownership in return. Deal valued at up to $47 million through equity, convertible notes, milestone-based funding, and warrant coverage. Oramed retains responsibility for POD clinical program including planned 60-patient U.S. trial for ORMD-0801. Oramed also receives 4% royalties on ReWalk franchise net sales for up to 10 years.
  • Hefei Tianhui Biotech Co. Ltd. (HTIT)coreStrategic or Co-development Partner · 23 October 2025Joint venture with Chinese partner HTIT for oral insulin development and commercialization. HTIT completed Phase 3 oral insulin trials in China and submitted Marketing Authorization Application to NMPA. HTIT committed $70 million in cash to the JV while Oramed invested $25 million in cash and stock. Oramed terminated the joint venture in 2025 to proceed independently with its oral insulin program.
  • MedicoxregionalChannel Partner/ Reseller/ Distributor · 18 November 2022Distribution agreement with Medicox for commercialization of oral insulin in South Korea. Oramed signed definitive deal for oral insulin distribution through Medicox's established pharmaceutical distribution network.
  • Genomma Lab InternacionalregionalStrategic or Co-development Partner · 18 November 2021Joint venture between Oramed's subsidiary Oravax Medical and Genomma Lab for development and commercialization of oral COVID-19 vaccine in Mexico and Latin America. Genomma Lab brings local market expertise and distribution capabilities.
  • Hadassah Medical CentercoreTechnology or Integration · 28 February 2018POD technology based on over 30 years of research by scientists at Jerusalem's Hadassah Medical Center. The research partnership provides the foundational scientific basis for Oramed's oral delivery platform technology.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Oramed Pharmaceuticals competitors and assessment

Company assessment

Broad incumbents

  • Sanofi: Major insulin manufacturer (Lantus, Toujeo, Apidra) with established global diabetes infrastructure. Sanofi represents incumbent competition for any oral insulin entrant and has the resources to develop or acquire competing oral delivery technology.
  • Novo Nordisk: Global leader in diabetes care with dominant insulin and GLP-1 franchises (Ozempic, Wegovy, Rybelsus — the only currently approved oral GLP-1). Novo Nordisk is the primary competitive incumbent Oramed would face in any oral insulin or oral GLP-1 launch.
  • Eli Lilly: Major diabetes/obesity player with injectable insulin and the leading injectable GLP-1 franchise (Mounjaro/Zepbound). Lilly's scale, manufacturing, and commercial reach make it a direct competitive threat to any oral diabetes entrant.

Emerging players

  • Diasome Pharmaceuticals: Clinical-stage company developing oral hepatic-directed vesicle (HDV) insulin and other liver-targeted therapies for diabetes. Diasome is an emerging player working on alternative oral insulin delivery approaches with comparable patient target.
  • Zealand Pharma: Clinical-stage peptide therapeutics company developing long-acting GLP-1 analogs and other peptide-based treatments. Zealand Pharma is an emerging peer in the GLP-1 space, directly relevant to Oramed's ORMD-0901 oral exenatide program.
  • Intarcia Therapeutics: Developed an implantable osmotic pump for continuous delivery of diabetes therapies, representing another approach to reducing injection burden. Intarcia is a thematically comparable emerging peer in long-acting / non-injectable diabetes delivery.
  • Biocon Biologics: India-based biosimilar insulin and biologic manufacturer with growing global commercial reach. Biocon is an emerging peer in the broader insulin market and a potential strategic partner or competitor for affordable insulin analogs.
  • vTv Therapeutics: Clinical-stage company developing orally bioavailable small molecules for type 1 diabetes (TTP399) and other metabolic diseases. vTv is an emerging peer in oral diabetes therapeutics, though pursuing a different mechanism than peptide delivery.

Direct peers

  • Adocia: French clinical-stage biotech developing oral formulations of insulin and GLP-1 analogs using BioChaperone technology. Adocia is the closest direct competitor in oral peptide delivery; Oramed's VP of Medical Affairs (Dr. Simon Bruce) was formerly CMO of Adocia.
  • MannKind Corporation: Developed and commercializes Afrezza, an inhaled insulin, addressing the same unmet need Oramed targets: reducing the injection burden for diabetes patients. MannKind is a directly comparable non-invasive insulin delivery peer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Oramed Pharmaceuticals social profiles

Digital presence

Oramed Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Oramed Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles15 records

Oramed Pharmaceuticals subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Oramed Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Oramed Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments4 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oramed Pharmaceuticals

What does Oramed Pharmaceuticals do?

Oramed is a clinical-stage pharmaceutical company developing its proprietary Protein Oral Delivery (POD™) platform technology, which enables oral administration of drugs currently delivered by injection. Its lead clinical candidates are ORMD-0801, an oral insulin capsule targeting Type 2 diabetes (and under evaluation for NASH), and ORMD-0901, an oral GLP-1 analog (exenatide) capsule. The company also licenses/transfer the POD platform to partners (e.g., Lifeward, HTIT, Medicox, Genomma Lab) and holds strategic biomedical investments in companies such as Scilex Holding and Alpha Tau Medical.

Is Oramed Pharmaceuticals a public or private company?

Oramed Pharmaceuticals is a public company. It is classified as public and is currently operating.

When was Oramed Pharmaceuticals founded?

Oramed Pharmaceuticals was founded in 2006. It employs 11 to 50 people.

Where is Oramed Pharmaceuticals based?

Oramed Pharmaceuticals is headquartered in Jerusalem, Israel, in the Middle East region.

How does Oramed Pharmaceuticals make money?

Four revenue lines are on record. Strategic Investment Returns are the primary driver. The others are warrant and Equity Holdings, technology Licensing and Royalties and pharmaceutical Development.

Who are Oramed Pharmaceuticals's main competitors?

Broad incumbents on record are Sanofi, Novo Nordisk and Eli Lilly. Emerging players are Diasome Pharmaceuticals, Zealand Pharma, Intarcia Therapeutics, Biocon Biologics and vTv Therapeutics. Direct peers are Adocia and MannKind Corporation.

Does Oramed Pharmaceuticals have an API?

No public API is recorded for Oramed Pharmaceuticals.

What industry is Oramed Pharmaceuticals in?

Oramed Pharmaceuticals's product category is Oral Insulin and Diabetes Therapeutics. Its primary akta.pro industry code is HLAIAAAJ, Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
American Banking and Market NewsModerna (NASDAQ:MRNA) and Oramed Pharmaceuticals (NASDAQ:ORMP) Financial ContrastModerna and Oramed Pharmaceuticals are compared on profitability, valuation, and institutional ownership. Moderna has a consensus price target of $107.10, implying a 51.70% downside, while Oramed beats Moderna on 9 of 13 factors. Moderna's beta is 1.09 versus Oramed's 1.29.MarketBeatOramed Pharmaceuticals (NASDAQ:ORMP) Stock Breaks Below Two Hundred Day Moving Average - Time to Sell?Oramed Pharmaceuticals shares fell below its 200-day moving average on Wednesday, trading at $4.14. The stock has a 200-day average of $4.27, and analysts rate it a Hold. Insiders sold shares, and the company reported a loss of $0.09 EPS for the quarter.Ticker ReportContrasting Oramed Pharmaceuticals (NASDAQ:ORMP) & Generate Biomedicines (NASDAQ:GENB)Generate Biomedicines and Oramed Pharmaceuticals are compared on valuation, profitability, and analyst ratings. Generate Biomedicines has a stronger consensus rating and a higher potential upside of 84.10% versus Oramed's 2.00 score. The company's lead product GB-0895 is in Phase 3 trials for severe asthma.Defense WorldContrasting Recursion Pharmaceuticals (NASDAQ:RXRX) & Oramed Pharmaceuticals (NASDAQ:ORMP)Oramed Pharmaceuticals and Recursion Pharmaceuticals are compared on analyst ratings, earnings, and valuation. Recursion has a stronger consensus rating and higher upside, while Oramed shows higher earnings but lower revenue. Recursion's price-to-earnings ratio is lower, making it more affordable.American Banking and Market NewsFinancial Contrast: Recursion Pharmaceuticals (NASDAQ:RXRX) vs. Oramed Pharmaceuticals (NASDAQ:ORMP)A stock comparison between Oramed Pharmaceuticals and Recursion Pharmaceuticals evaluates profitability, valuation, and analyst ratings. Recursion has higher institutional ownership (89.1% vs 12.7%) and a lower P/E ratio, with a consensus target price of $8.06 implying 88.76% upside. Oramed beats on 9 of 14 factors.American Banking and Market NewsOramed Pharmaceuticals (NASDAQ:ORMP) and Generate Biomedicines (NASDAQ:GENB) Financial AnalysisGenerate Biomedicines and Oramed Pharmaceuticals are compared on profitability, valuation, and analyst ratings. Generate Biomedicines has a stronger consensus rating and a $26.40 target price, implying 92.84% upside, while Oramed has lower revenue but higher earnings. Generate Biomedicines' GB-0895 is in Phase 3 for severe asthma, with first patient dosed in January 2026.Investing.comOramed Pharmaceuticals CFO Avraham Gabay sells $90,200 in stockOramed Pharmaceuticals CFO Avraham Gabay sold 20,000 shares on October 1, 2026, for $90,200 under a Rule 10b5-1 plan. The stock has risen 92% over the past year, trading at $4.49 with a market cap of $184.69 million. Shareholders approved all proposals at the 2026 annual meeting.Ticker ReportOramed Pharmaceuticals (NASDAQ:ORMP) versus BioMarin Pharmaceutical (NASDAQ:BMRN) Critical ReviewBioMarin Pharmaceutical beats Oramed Pharmaceuticals on 11 of 15 factors, including revenue, earnings, and analyst ratings. BioMarin has a consensus target price of $89.17, implying 39.46% upside, while Oramed trades at a lower P/E but lower profitability. BioMarin's institutional ownership is 98.7% versus Oramed's 12.7%.Investing.comOramed Pharmaceuticals shareholders approve board, stock plan amendment at annual meeting By Investing.comOramed Pharmaceuticals shareholders approved all six proposals at its 2026 annual meeting, including re-election of directors and ratification of the accounting firm. The stock plan amendment increased authorized shares by 3 million to 12.5 million, and the say-on-pay vote passed with a three-year interval selected.Seeking AlphaOramed Pharmaceuticals: Hold Reiterated As Alpha Tau Investment Delivers And More (ORMP)Oramed Pharmaceuticals maintains a Hold rating as it pivots to strategic investments, with its Alpha Tau Medical stake near tripling to $38.2M and a loan recovery from Scilex. The company's cash position is tight at $15.24M, providing only a 12-month runway, raising dilution risks if new deals or asset sales do not materialize.